AIM: To determine whether magnetic resonance imaging (MRI) can be used to categorize small bowel Crohn's disease (SB CD) into groups that correlate with response to medical therapy and surgical pathology. METHODS: Data was collected from all patients with MRI evidence of SB CD without significant colonic disease over a 32-mo period. Two radiologists, blinded to clinical findings, evaluated each MRI and grouped them based on bowel wall thickness and wall enhancement. These categories were: (1) "fibrosis", (2) "mild segmental hyper-enhancement and mild wall thickening", (3) "mild segmental hyper-enhancement and marked wall thickening", (4) "marked segmental transmural hyper-enhancement". Patient response to additional medical therapy post-MRI was prospectively determined at 8-wk. Non-responders underwent endoscopy and were offered therapeutic endoscopy or surgery. Surgical pathology was assessed against the MRI category. RESULTS: Fifty-five patients were included. Females and category "2" patients were more likely, and patients with luminal narrowing and hold-up less likely, to respond to medical therapy (P < 0.05). Seventeen patients underwent surgery. The surgical pathological findings of fibrosis and the severity of inflammation correlated with the MRI category in all cases. CONCLUSION: Our findings suggest that SB CD can be grouped by the MRI findings and that these groups are associated with patients more likely to respond to continued medical therapy. The MRI categories also correlated with the presence and level of intestinal inflammation and fibrosis on surgical pathology, and may be of prognostic use in the management of CD patients.
AIM: To determine whether magnetic resonance imaging (MRI) can be used to categorize small bowel Crohn's disease (SB CD) into groups that correlate with response to medical therapy and surgical pathology. METHODS: Data was collected from all patients with MRI evidence of SB CD without significant colonic disease over a 32-mo period. Two radiologists, blinded to clinical findings, evaluated each MRI and grouped them based on bowel wall thickness and wall enhancement. These categories were: (1) "fibrosis", (2) "mild segmental hyper-enhancement and mild wall thickening", (3) "mild segmental hyper-enhancement and marked wall thickening", (4) "marked segmental transmural hyper-enhancement". Patient response to additional medical therapy post-MRI was prospectively determined at 8-wk. Non-responders underwent endoscopy and were offered therapeutic endoscopy or surgery. Surgical pathology was assessed against the MRI category. RESULTS: Fifty-five patients were included. Females and category "2" patients were more likely, and patients with luminal narrowing and hold-up less likely, to respond to medical therapy (P < 0.05). Seventeen patients underwent surgery. The surgical pathological findings of fibrosis and the severity of inflammation correlated with the MRI category in all cases. CONCLUSION: Our findings suggest that SB CD can be grouped by the MRI findings and that these groups are associated with patients more likely to respond to continued medical therapy. The MRI categories also correlated with the presence and level of intestinal inflammation and fibrosis on surgical pathology, and may be of prognostic use in the management of CDpatients.
Authors: Andreas G Schreyer; Johannes Seitz; Stefan Feuerbach; Gerhard Rogler; Hans Herfarth Journal: Inflamm Bowel Dis Date: 2004-01 Impact factor: 5.325
Authors: Russell N Low; Christopher P Sebrechts; Douglas A Politoske; Michael T Bennett; Sergio Flores; Richard J Snyder; Jeffrey H Pressman Journal: Radiology Date: 2002-03 Impact factor: 11.105
Authors: P H Harper; V W Fazio; I C Lavery; D G Jagelman; F L Weakley; R G Farmer; K A Easley Journal: Dis Colon Rectum Date: 1987-03 Impact factor: 4.585
Authors: Yunhao Zhu; Laura A Johnson; Ziyi Huang; Jonathan M Rubin; Jie Yuan; Hao Lei; Jun Ni; Xueding Wang; Peter D R Higgins; Guan Xu Journal: Biomed Opt Express Date: 2018-03-08 Impact factor: 3.732
Authors: Hao Lei; Laura A Johnson; Shengchun Liu; David S Moons; Teng Ma; Qifa Zhou; Michael D Rice; Jun Ni; Xueding Wang; Peter D R Higgins; Guan Xu Journal: Biomed Opt Express Date: 2016-06-27 Impact factor: 3.732